CAR T cells are deficient in recognizing tumor cells expressing low levels of target antigen, providing an opportunity for immune escape through antigen downregulation, as has been observed in clinical trials of CD22 and BCMA CARs10–12. This evidence concerns the gene TNFRSF17 and neoplasm.